Discontinued — last reported Q4 '25
Business Segments · Restructuring (Note 12)
Innovative Medicine — Restructuring (Note 12)
Year-over-year, this metric declined by 100.0%, from $2.00M to $0.00. Over 4 years (FY 2021 to FY 2025), Innovative Medicine — Restructuring (Note 12) shows relatively stable performance with a 0.0% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementSegment
CategoryEfficiency
SignalLower is better
VolatilityVolatile
First reportedQ1 2021
Last reportedQ4 2025Feb 11, 2026
Rolls up toRestructuring Charges
How to read this metric
While initially a cost, these expenses are often incurred to drive future margin expansion and operational agility.
Detailed definition
These are costs associated with organizational changes, facility closures, or workforce reductions specifically within t...
Peer comparison
Commonly reported as 'Restructuring Charges' by large-cap companies undergoing strategic transformations.
Metric ID:
jnj_segment_innovative_medicine_restructuring_note_12Historical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $25.00M | $25.00M | $25.00M | $25.00M | $25.00M | $25.00M | $25.00M | $100.00M | $100.00M | $149.00M | $76.00M | $144.00M | -$63.00M | $19.00M | $2.00M | $100.00M | $0.00 | $0.00 | $0.00 |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +300.0% | +0.0% | +49.0% | -49.0% | +89.5% | -143.8% | +130.2% | -89.5% | >999% | -100.0% | — | — |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +300.0% | +300.0% | +496.0% | +204.0% | +44.0% | -163.0% | -87.2% | -97.4% | -30.6% | +100.0% | -100.0% | -100.0% |
Range-$63.00M – $149.00M
CAGR-100.0%
Avg YoY Growth+57.7%
Median YoY Growth+0.0%
Current Streak3 quarters decline
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's innovative medicine — restructuring (note 12)?
- Johnson & Johnson (JNJ) reported innovative medicine — restructuring (note 12) of $0.00 in Q4 2025.
- How has Johnson & Johnson's innovative medicine — restructuring (note 12) changed year-over-year?
- Johnson & Johnson's innovative medicine — restructuring (note 12) decreased by 100.0% year-over-year, from $2.00M to $0.00.
- What is the long-term trend for Johnson & Johnson's innovative medicine — restructuring (note 12)?
- Over 4 years (2021 to 2025), Johnson & Johnson's innovative medicine — restructuring (note 12) has grown at a 0.0% compound annual growth rate (CAGR), from $100.00M to $100.00M.
- What does innovative medicine — restructuring (note 12) mean?
- Expenses related to reorganizing or downsizing parts of the pharmaceutical business to improve efficiency.